Clinical Trial Update: Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating topical ALT-2074 (SYI-2074) for chronic plaque psoriasis has been terminated. The update discusses its efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• ALT-2074 (SYI-2074) (ALT-2074)

Snippet

Sponsor: Synvista Therapeutics, Inc | Conditions: Psoriasis | Phase 2 | Status: TERMINATED